Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sumatriptan
Drug ID BADD_D02098
Description Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.[A179761] Sumatriptan was granted FDA approval on 28 December 1992.[L6805]
Indications and Usage A combination sumatriptan and [naproxen] tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older.[L6793] Sumatriptan nasal powder, nasal spray, subcutaneous injection, and tablets are indicated to treat migraines with or without auras in adults.[L6796,L6799,L6805,L6808,L6811] One of the subcutaneous formulations of sumatriptan is also indicated to treat cluster headaches in adults[L6805], while the other subcutaneous formulation is not.[L6808]
Marketing Status approved; investigational
ATC Code N02CC01
DrugBank ID DB00669
KEGG ID D00451
MeSH ID D018170
PubChem ID 5358
TTD Drug ID D0Z6UC
NDC Product Code 80425-0258; 52932-0733; 42043-220; 65145-118; 72189-404; 62331-048; 42043-222; 55150-173; 55700-969; 63629-8701; 0173-0737; 55700-918; 70069-804; 0527-1859; 63304-097; 69452-344; 0480-2014; 45802-619; 0173-0736; 0245-0812; 60429-995; 63304-098; 63304-099; 53873-058; 67835-5011; 0173-0479; 0173-0524; 66993-084; 0527-1818; 36000-289; 66993-082; 69452-345; 69452-346; 71921-170; 58437-017; 0143-9638; 0173-0523; 63187-164; 63187-323; 63629-8703; 69097-644; 80425-0318; 50370-0029; 53873-057; 58437-016; 58437-018; 0173-0735; 53002-3562; 66993-083; 80425-0224; 53873-059; 42043-221; 0173-0478; 66993-081; 68071-2825; 0480-2013; 45802-598; 0173-0739
UNII 8R78F6L9VO
Synonyms Sumatriptan | 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide | Sumatriptan Succinate | Succinate, Sumatriptan | GR-43175 | GR 43175 | GR43175 | Imigran
Chemical Information
Molecular Formula C14H21N3O2S
CAS Registry Number 103628-46-2
SMILES CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arrhythmia02.03.02.001--Not Available
Arteriosclerosis24.04.02.001--Not Available
Arteriospasm coronary02.02.02.005; 12.02.01.031; 24.04.04.005--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Asthenia08.01.01.0010.000395%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.002--Not Available
Atrophy08.03.04.001--Not Available
Back pain15.03.04.005--
Bladder pain20.02.02.001--Not Available
Blindness06.02.10.003; 17.17.01.003--Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood thyroid stimulating hormone increased13.10.03.006--
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Breast cancer21.05.01.003; 16.10.01.001--Not Available
Breast cyst21.05.01.006; 16.14.01.004--Not Available
Breast discharge21.05.05.001--Not Available
Breast feeding26.05.01.001--Not Available
Breast mass21.05.04.002--Not Available
Breast swelling21.05.05.008--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm22.03.01.004; 10.01.03.012--
Burning sensation17.02.06.001; 08.01.09.0290.000284%Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000056%Not Available
Cardiomyopathy02.04.01.001--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene